bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference

by Maria Zannes | Sep 7, 2023 | Press Releases

SAN ANTONIO, Texas (Sept. 7, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that Maria Zannes, President and CEO, will present a corporate...

bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update

by Maria Zannes | Aug 10, 2023 | Press Releases

SAN ANTONIO, Texas (Aug. 14, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three...

AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer

by Maria Zannes | Jul 12, 2023 | Press Releases

SAN ANTONIO, Texas (July 12, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that the American Medical Association (AMA) has released a...

bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium

by Maria Zannes | Jun 15, 2023 | Press Releases

SAN ANTONIO, Texas (June 15, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for early-stage cancer detection and broad-spectrum cancer therapeutics, will present the poster “Vitamin B12 deprivation does not...

bioAffinity Technologies Presents Research Findings at CYTO 2023

by Maria Zannes | May 22, 2023 | Press Releases

SAN ANTONIO, Texas (May 22, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today will present the poster “Development of...

bioAffinity Technologies Reports First Quarter 2023 Financial Results

by Maria Zannes | May 15, 2023 | Press Releases

SAN ANTONIO, Texas (May 15, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three...
« Older Entries
Next Entries »

Categories

  • Articles (27)
  • Events (38)
  • News (52)
  • Press Releases (123)
  • Publications (17)

Recent Posts

  • bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung June 3, 2025
  • bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics May 28, 2025
  • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer May 20, 2025
  • bioAffinity Technologies Reports First Quarter 2025 Results May 15, 2025
  • Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer May 8, 2025

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.